Skip to main content

Table 2 Progress free survival time and overall survival time of patients before and after PSM

From: Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study

Variable

N

OS (months)

PFS (months)

Median

95%CI

Median

95%CI

Before PSM

     

AS

62

13.27

11.35–15.19

10.07

8.40–12.09

SOX

81

11.17

9.61–12.72

6.70

5.51–7.89

AS (non-intestinal)

58

13.27

11.46–15.09

10.07

8.12–12.02

SOX (non-intestinal)

55

9.90

7.71–12.09

6.53

4.31–8.76

AS (diffuse)

42

14.23

11.70–16.77

10.07

7.81–12.33

SOX (diffuse)

35

8.83

6.67–11.00

4.60

3.54–5.66

After PSM

     

AS

54

14.13

11.96–16.31

10.30

7.06–13.54

SOX

54

11.17

9.09–13.24

6.70

6.08–7.33

AS (non-intestinal)

50

14.23

12.14–16.33

10.30

7.53–13.07

SOX (non-intestinal)

39

9.90

7.30–12.50

6.87

5.26–8.48

AS (diffuse)

34

15.93

13.58–18.28

10.30

7.27–13.33

SOX (diffuse)

24

8.83

6.51–11.15

4.60

2.25–6.95

  1. OS, overall survival time; PFS, progress free survival time; CI, confidence intervals; non-intestinal, including diffuse lauren type and mixed lauren type; PSM, propensity score matching; N, number